Eluminex Biosciences announced that their tri-specific fusion antibody drug, EB-105, has administered its first dose to a diabetic macular edema patient in the United States. This clinical trial, known as LOTUS, is an open-label, multicenter, single-dose, dose-escalation clinical trial via intravitreal injection, currently being conducted in four hospitals across the United States.

On July 22, 2024, Foreseen Biotechnology announced the exclusive global licensing of their ADC targeted drug, FS001, to Ipsen Pharma SAS of France. Ipsen will have exclusive rights to develop, manufacture, and commercialize FS001 worldwide. The total licensing fee, including upfront payments, milestone payments, and sales royalties, amounts to US$1.03 billion.

Eluminex Biosciences's preclinical studies have shown that EB-105 can effectively inhibit signal transduction pathways such as VEGF-A/VEGFR-2, Ang-2/Tie-2, and IL-6/IL-6R. In addition to targeting vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), EB-105 also inhibits intracellular inflammation-related signal transduction pathways, potentially offering better therapeutic effects for patients with diabetic retinopathy compared to current therapies.

Foreseen Biotechnology's ADC targeted drug, FS001, is based on a novel tumor-associated antigen discovered by Foreseen Biotechnology. It has excellent targeting activity and high specificity. FS001 uses an innovative, stable, cleavable linker, coupled with a highly effective topoisomerase I inhibitor, demonstrating promising preclinical efficacy in various drug-resistant cancer models.

Sanyou Bio assisted Eluminex Biosciences and Foreseen Biotechnology in the crucial work of discovering the above innovative drugs.

Dr. Guojun Lang, CEO of Sanyou Bio, remarked: "Sanyou Bio is honored to have supported Eluminex Biosciences and Foreseen Biotechnology in their discovery of innovative biologic drugs! We wish for the continued success of these projects in the subsequent R&D, and hope they achieve clinical success soon to benefit patients worldwide!"